Senores Pharmaceuticals Ltd. · NSE:SENORES
Senores Pharmaceuticals — FY2025 Earnings Presentation
37 slides from Senores Pharmaceuticals's earnings presentation, May 2025
Slide 1: Investor Presentation May 2025
Investor Presentation May 2025
Slide 2: Safe Harbor
Safe Harbor This presentation and the accompanying slides (the “Presentation”), which have been prepared by Senores Pharmaceuticals Limited (the “Company” / “SPL”), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscri
Slide 3: Financial Highlights Q4 and FY25
Financial Highlights Q4 and FY25 Private & Confidential
Slide 4: Key Operational Highlights
Key Operational Highlights Regulated Markets Emerging Markets 22 28 285 Owned Commercial Products Pipeline CGT Opportunity Products Approved Products 61 22 636 Approved ANDA Products CDMO/CMO Commercial Products Products Under Registration 51 69 40 + Pipeline Products CDMO/CMO Pipeline Products Coun
Slide 5: Consolidated Financial Highlights – Q4 & FY25
Consolidated Financial Highlights – Q4 & FY25 Income up by 91% EBIDTA up by 145% PBT up by 183% Y-o-Y for FY25 Y-o-Y for FY25 Y-o-Y for FY25 Income (INR Crs)* EBITDA (INR Crs) PBT (INR Crs) +131.7% 89.2% 183.0% 410.4 101.8 70.6 17.3% +13.3% +17.5% 216.9 43.9 120.1 20.7 24.9 102.4 22.4 25.4 17.6 Q4FY
Slide 6: Business Segment Financial Highlights – Q4 & FY25
Business Segment Financial Highlights – Q4 & FY25 Regulated Markets Emerging Markets Others +174.1% +68.7% +76.2% Revenue (INR Crs) 244.8 121.2 44.4 +90.1% +17.4% 145.2 -2.7% 25.2 44.2 19.3 64.3 37.5 36.5 54.8 10.2 Q4 FY24 Q4 FY25 FY24 FY25 Q4 FY24 Q4 FY25 FY24 FY25 Q4 FY24 Q4 FY25 FY24 FY25 EBIDTA
Slide 7: Management Commentary
Management Commentary Commenting on the Q4 & FY25 performance of the company Mr. Swapnil Shah, Managing Director for Senores Pharmaceuticals Limited said, “We are pleased to report strong performance for FY25, driven by our strategy of developing niche products for Regulated Markets and expanding ou
Slide 8: Consolidated Profit & Loss Account – Q4 & FY25
Consolidated Profit & Loss Account – Q4 & FY25 Profit and Loss (INR Crs) Q4 FY25 Q4 FY24 YoY FY25 FY24* YoY Revenue 108.7 97.4 11.6% 390.8 209.0 87.0% Other Operating Income 11.5 5.0 19.5 7.9 Total Income 120.2 102.4 17.3% 410.4 216.9 89.2% Total COGS 57.5 45.4 180.7 106.1 Gross Profit 62.7 57.0 9.9
Slide 9: Other Financial Highlights – Q4 & FY25
Other Financial Highlights – Q4 & FY25 Particulars (Rs Crs) Q4FY25 Q4FY24 FY25 FY24 A: Other Operating Income Product related service Income 4.91 3.78 7.68 4.13 Miscellaneous - Other Operating Income 7.24 2.03 7.94 2.72 Gain on Foreign Exchange Fluctuation (Net) -0.67 0.89 3.92 1.07 Total Other Oper
Slide 10: Consolidated Balance Sheet
Consolidated Balance Sheet ASSETS (INR Crs) Mar-25 Mar-24 EQUITY AND LIABILITIES (INR Crs) Mar-25 Mar-24 Non-Current Assets Equity Property, Plant and Equipment 198.9 152.2 Equity Share Capital 46.1 30.5 Capital Work-in-Progress 44.2 17.8 Other Equity 740.1 173.8 Goodwill 38.2 38.2 Total Shareholder
Slide 11: Consolidated Abridged Cash Flow Statement
Consolidated Abridged Cash Flow Statement Cash Flow Statement (INR Mn) FY25 FY24 Profit/(Loss) Before Tax 70.6 24.9 Adjustments for Non-Cash and Non-Operational Expenses / (Incomes) 27.1 17.9 Operating Profit / (Loss) Before Working Capital Changes 97.7 42.8 Changes in Working Capital -134.4 -66.1 C
Slide 12: Update on Utilization of Funds from IPO
Update on Utilization of Funds from IPO Amount as proposed in Amount utilized as on Amount Unutilized as on Sr. No Object as per Offer Document Remarks the Offer Document March 31, 2025 March 31, 2025 Investment in one of our Subsidiaries, Havix, to fund capital expenditure requirements for setting
Slide 13: About Senores Pharmaceuticals Limited
About Senores Pharmaceuticals Limited Private & Confidential
Slide 14: Introduction to Senores Pharma
Introduction to Senores Pharma Brief Overview At a Glance Global Research driven Formulation Focused company engaged in developing & manufacturing of pharmaceutical products predominantly for the Regulated Markets of the US, Canada & UK across various therapeutic areas Niche Product Identification C
Slide 15: Business Segments
Business Segments FY25 Income 59.7% 29.5% 10.8% INR 410 Crs Regulated Markets Emerging Markets Others (API + Injectables + Other Op. Income Regulated Markets Business Emerging Markets Business Develop & manufacture pharmaceutical products for the Primarily serves the US, Canada and United Kingdom Em
Slide 16: Key Events & Milestones
Key Events & Milestones Consolidated presence in emerging Commenced manufacturing activities at Incorporated as “Senores markets by acquiring shares in its greenfield API plant located at Incorporated a wholly owned subsidiary, Pharmaceuticals Pvt. Ltd.” in India. Ratnatris Pharmaceuticals Pvt. Ltd.
Slide 17: Key Strengths
Key Strengths Private & Confidential
Slide 18: Key Strengths of the Company
Key Strengths of the Company 1 Distinct specialty and complex product portfolio built in a short span for Regulated Markets 2 Long-term marketing arrangements with pharmaceutical companies in the Regulated Markets 3 Presence in the Emerging Markets with portfolio, including specialty and complex pro
Slide 19: Distinct Specialty & Complex Product Portfolio Built in a Short Span for Regulated Markets
1 Distinct Specialty & Complex Product Portfolio Built in a Short Span for Regulated Markets Demonstrated Capability to propel Products from Conception to Commercialization ANDA Products Product Identification Product Development Commercial Data Analysis – IQVIA, R&D to establish API Concurrent Part
Slide 20: Presence in Regulated Markets through Long-term marketing arrangements
2 Presence in Regulated Markets through Long -term marketing arrangements MARKETED PRODUCTS CDMO / CMO Business Model Business Model Identify, Develop & Commercialize specialty & complex Customized formulation, development & manufacturing niche products in mid - market range capabilities for custome
Slide 21: Presence in the Emerging Markets with Portfolio Including Specialty and Complex Products
3 Presence in the Emerging Markets with Portfolio Including Specialty and Complex Products Special Focus Niche & Specialty patented products in the US with early launch 403 opportunity in Emerging Markets 87 South East 40+ Commonwealth of Asia Countries Sugammadex Ferric Independent Marketed States
Slide 22: Partners to Global Pharmaceutical Companies in Regulated & Emerging Markets
Partners to Global Pharmaceutical Companies in Regulated & Emerging Markets 22
Slide 23: Strong R&D Capabilities Driving Differentiated Product Portfolio
Strong R&D Capabilities Driving Differentiated Product Portfolio R&D Site 1 - USA Identify Oral Oral ▪ Internal research ORS Injectables API Solids Liquids ▪ In-House R&D in US ▪ Information available for Controlled on subscribed Substances databases R&D Site 2 - India Team ▪ Helps in dossier ▪ 64 p
Slide 24: Accredited Manufacturing Facilities
5 Accredited Manufacturing Facilities Atlanta Facility Ahmedabad, Chhatral Facility Facility 35,205 Sq. Mtr. Total Area 2 Manufacturing Lines 12 185,300 Sq. Ft. Manufacturing Lines Total Area 4 OSD Dosage Forms 1.2 Bn units Annual Installed General Oral Beta Lactum Capacity Strong Regulatory Track R
Slide 25: Corporate Structure
Corporate Structure Group holding company based in India Houses Domestic Critical Care Injectables business & API business Senores Pharmaceuticals Inc. Marketing cum ANDA Havix Group Inc Ratnatris Pharmaceuticals Pvt. Ltd. Caters to Regulated Market Caters to Emerging Market Holding Company US based
Slide 26: Professional and Dedicated Management Team
6 Professional and Dedicated Management Team Swapnil Jatinbhai Shah Sanjay Shaileshbhai Majmudar Deval Rajnikant Shah Promoter & Managing Director Chairman & Non-Executive, Non- Whole-Time Director & CF O Independent Director ▪ 17+ years of experience in the pharma sector ▪ 40+ years of experience ▪
Slide 27: Growth Strategies
Growth Strategies Private & Confidential
Slide 28: Key Strategies
Key Strategies Inorganic growth Significantly enhance market through synergistic presence in North America & acquisitions other Regulated Markets Integrated approach by Launch products with the enhancing capabilities for potential of NDA approval in backward integration the US Strategic alliance for
Slide 29: Enhance Market Presence of Marketed Products in North America and Other Regulated Markets
Enhance Market Presence of Marketed Products in North America and Other Regulated Markets US accounts for 43% of the global pharma market, 56% of the regulated market & 91% Persistent drug shortage calls for an of North America Market increased supply of generic drugs Global pharma market by classif
Slide 30: Entering into Strategic Alliance for CMO/CDMO in Regulated Markets
Entering into Strategic Alliance for CMO/CDMO in Regulated Markets CDMO market growing faster than the pharma market Strategic alliance for CMO/CDMO in Regulated Markets which is growing at 7.7% US CDMO/CMO market (USD bn) The dependence on CDMO/CMO’s has increased as they offer 7.7% Appended Manufa
Slide 31: Expanding into New Regulated & Emerging Markets
Expanding into New Regulated & Emerging Markets Regulated & Emerging markets witnessing strong growth Global pharma market by classification (USD bn) Emerging pharma market by Product (2028F) Regulated pharma market by Product (2028F) Regulated Emerging Innovator Generic Generic Innovator 541.0 376.
Slide 32: Enhancing Capabilities for Backward Integration
Enhancing Capabilities for Backward Integration Indian API export market to grow at a CAGR of 8.4% Pursuing an integrated approach for greater backward integration API exports (USD bn) Setup Greenfield unit - Increase API manufacturing capacity CAGR: 8.4% Proposed from 25 MTPA to 169 MTPA 7.1 Expans
Slide 33: Industry Overview
Industry Overview Private & Confidential
Slide 34: Global Pharma Market
Global Pharma Market Global pharma market is expected to grow at …regulated market will continue to dominate the US continues to exert influence on Global pharma market 6.6% from 2023-28… global pharma market Global pharma market by product type (USD bn) Global pharma market by region (USD bn) Share
Slide 35: Regulated Pharma Market
Regulated Pharma Market Regulated markets to dominate the global pharmaceutical sector, driven by their access to a growing innovative drug market & a thriving generics market Regulated markets constitute 77% of the global North America accounts for 62% of regulated New generics and patent expiratio
Slide 36: Emerging Pharma Market
Emerging Pharma Market Emerging pharma market Overview of India pharma market Emerging markets to outpace developed ones… IPM is amongst the fastest growing in the Oral solids will dominate IPM world… Emerging pharma market size (USD bn) Indian pharma market size (USD bn) Indian pharma market by dos
Slide 37: Senores Pharmaceuticals Limited – Contact Us
SENORES PHARMACEUTICALS LIMITED CONTACT US Senores Pharmaceuticals Limited Strategic Growth Advisors Private Limited CIN: L24290GJ2017PLC100263 CIN: U74140MH2010PTC204285 Mr. Deval Shah – Whole Time Director & CFO Mr. Sagar Shroff / Mr. Tanay Shah sagar.shroff@sgapl.net / tanay.shah@sgapl.net +91 98
Senores Pharmaceuticals — FY2025 Earnings Presentation on 6ix